Literature DB >> 10624794

Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.

B Y Zeng1, B Dass, A Owen, S Rose, C Cannizzaro, B C Tel, P Jenner.   

Abstract

The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with L-DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic L-DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic L-DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity may be altered by L-DOPA's action and this may be related to the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10624794     DOI: 10.1016/s0304-3940(99)00762-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

Review 1.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

4.  Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.

Authors:  Silva Fredduzzi; Rosario Moratalla; Angela Monopoli; Beatriz Cuellar; Kui Xu; Ennio Ongini; Francesco Impagnatiello; Michael A Schwarzschild; Jiang-Fan Chen
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 5.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 7.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.

Authors:  Alexander Kurz; Kay L Double; Isabel Lastres-Becker; Alessandro Tozzi; Michela Tantucci; Vanessa Bockhart; Michael Bonin; Moisés García-Arencibia; Silke Nuber; Falk Schlaudraff; Birgit Liss; Javier Fernández-Ruiz; Manfred Gerlach; Ullrich Wüllner; Hartmut Lüddens; Paolo Calabresi; Georg Auburger; Suzana Gispert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

9.  Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

Authors:  Sinéad Walsh; Katarzyna Mnich; Ken Mackie; Adrienne M Gorman; David P Finn; Eilís Dowd
Journal:  Brain Res Bull       Date:  2010-01-25       Impact factor: 4.077

Review 10.  The endocannabinoid system as a target for the treatment of motor dysfunction.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.